Treats platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. NDA 220641, held by Corcept Therap. Relacorilant.
As of Nov 13, 2026, NDA 220641 (Lifyorli (Copackaged)), held by Corcept Therap, was first approved by FDA on Mar 25, 2026, with 0 approved supplements and 0 published complete response letters.
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 25, 2026 | Original applicationNew molecular entity · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lifyorli (Copackaged)100MG;25MG · capsule;oral | Relacorilant | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
